Form 8-K - Current report:
SEC Accession No. 0001641172-25-015653
Filing Date
2025-06-18
Accepted
2025-06-18 17:29:15
Documents
13
Period of Report
2025-06-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 30086
  Complete submission text file 0001641172-25-015653.txt   255583

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE asbp-20250617.xsd EX-101.SCH 3800
3 XBRL DEFINITION FILE asbp-20250617_def.xml EX-101.DEF 28286
4 XBRL LABEL FILE asbp-20250617_lab.xml EX-101.LAB 37863
5 XBRL PRESENTATION FILE asbp-20250617_pre.xml EX-101.PRE 26498
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 7184
Mailing Address 23150 FASHION DRIVE, SUITE 232 ESTERO FL 33928
Business Address 23150 FASHION DRIVE, SUITE 232 ESTERO FL 33928 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41293 | Film No.: 251057957
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)